secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARIMED INC. (MRMD)
CIK:        0001522767
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001522767-25-000167
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY
----------------------------------------------------------------------

- Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.
- Non-GAAP adjusted EBITDA of $4.9M (12% margin), up from $4.4M (11% margin) in Q2 2024; company was cash flow positive.
- CEO cites 'Expand the Brand' strategy; growth in Massachusetts, full-quarter Delaware contributions, and entry into Pennsylvania.
- Six-month net loss widened to $6.7M from $2.9M, while non-GAAP net loss also widened; adjusted EBITDA margin fell to 10%.
- Company anticipates catalysts in H2: adult-use Delaware, new Maine license, Pennsylvania entry, and M&A optionality.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/0001522767-25-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/mrmd-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001522767-25-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer